Apollo Hospitals AICKD

• A Deep Learning Model, developed using Indian datasets, demonstrates superior accuracy compared to conventional risk scores.
• Feedback Loop from the prospective use in patients
• Comprehensive & Holistic Risk Assessment
• Validated at different National Institutions
• Integrated Clinical Decision Support Tool (What Next to Do)
• QMS: ISO 13485:2016 and MDSAP certified

Interpretation & Adoption Message

• AI Algorithm + Clinicians: This Disease progression Assessment tool has been built as an adjunct tool for physicians to identify the progression of CKD patients into different stages and End-stage renal failure.
• Risk Identification: This Disease Progression Assessment Tool is not intended for diagnosing chronic kidney disease (CKD). Its use is restricted to pediatric populations, individuals not diagnosed with CKD, those in CKD Stage 5, or patients undergoing treatments such as dialysis, transplants, or medications specifically targeting CKD progression.
• Where to use: This Disease progression assessment tool is designed for use at Outpatient Nephrology clinics, Inpatient Nephrology units, standalone Nephrology units, and Dialysis centers.